Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825104 | 0.84 | AR (0.43) | ARLOXL2LOXGRIN1GRIN2B | |
| SCHEMBL28393138 | 0.81 | NOS3 (0.46) | LOXL2CA2CHKANOS3NOS2 | |
| SCHEMBL15832232 | 0.81 | AR (0.46) | ARLOXL2LOXGRIN1GRIN2B | |
| SCHEMBL20241939 | 0.80 | ELOVL1 (0.43) | NOS3NOS2KDM4EELOVL1 | |
| SCHEMBL20241993 | 0.79 | ELOVL1 (0.42) | LOXL2NOS3NOS2L3MBTL1MAP4K4 | |
| SCHEMBL17356153 | 0.78 | AR (0.43) | ARLOXL2LOXGRIN1GRIN2B | |
| SCHEMBL31052478 | 0.76 | DHFR (0.44) | CA2CHKAIDH1PRMT6MAP4K4 | |
| SCHEMBL20242276 | 0.76 | ELOVL1 (0.40) | GRIN1GRIN2BRXRANOS3NOS2 | |
| SCHEMBL20242055 | 0.76 | LOX (0.38) | LOXL2LOXCYP17A1NOTUMELOVL1 | |
| SCHEMBL20241821 | 0.76 | ELOVL1 (0.36) | NOS3NOS2ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | AR 707/4885LOXL2 2328/4885LOX 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.